A hormone made by your adrenal glands could be the hidden reason your blood pressure refuses to budge, even with pills.
Story Snapshot
- CBS Mornings aired a World Heart Day segment on aldosterone, a hormone tied to persistent high blood pressure.
- Cardiologist Dr. Dmitry Yaranov, speaking on behalf of drugmaker AstraZeneca, explained how the hormone works.
- Medical research shows aldosterone-driven hypertension, called primary aldosteronism, affects far more people than once believed.
- Doctors say the condition is widely underdiagnosed, with less than one percent of eligible patients ever screened.
What CBS Mornings Told Viewers About The Hormone
CBS Mornings used World Heart Day to spotlight aldosterone, a hormone produced by the adrenal glands that helps control blood pressure. Dr. Dmitry Yaranov, a cardiologist and brand partner for AstraZeneca, joined the show to explain how too much of this hormone can keep blood pressure stubbornly high, even when patients take their prescribed medication every day.
Yaranov also discussed a newly approved prescription medicine built to target this exact problem. The segment framed aldosterone not as some obscure lab term, but as a practical reason why millions of people struggle to get their numbers down, despite following doctor’s orders and taking multiple drugs as directed.
Why This Hormone Problem Is More Common Than Most Patients Realize
This is not a fringe theory. Medical researchers have studied aldosterone’s role in hypertension for years. The condition, known as primary aldosteronism, shows up in roughly five to ten percent of all adults with high blood pressure, according to published reviews in the journal Hypertension. Among patients whose blood pressure resists treatment, that number climbs even higher.
Multiple clinical studies put the rate among resistant hypertension patients at ten to twenty percent, sometimes higher. A state-of-the-art review in the American Journal of Hypertension found overt cases ranging up to twenty-five percent of the hypertensive population studied. Other researchers tracking resistant cases specifically found primary aldosteronism in up to twenty percent of those patients.
The Bigger Problem: Almost Nobody Gets Tested For It
The real scandal in this story is not the science. It is the gap between what doctors know and what actually happens in exam rooms. Research published in Circulation found that among American patients with primary aldosteronism, only about one in 550 gets properly diagnosed and treated. That is a staggering miss rate for a fixable hormone problem.
Clinical reviewers have pointed to the same pattern repeatedly. If the condition affects five to ten percent of hypertensive adults, but fewer than one percent get screened for it, millions of Americans are taking blood pressure pills that may never fully solve their actual problem. Underdiagnosis, not lack of knowledge, is the real barrier here.
New Treatments Are Starting To Target The Hormone Directly
Drugmakers have taken notice. Researchers at University College London reported on a drug called baxdrostat, which works by reducing aldosterone levels directly rather than treating blood pressure through older mechanisms. Trial data showed the drug delivered unprecedented round-the-clock blood pressure control in patients whose numbers had stayed high despite other treatments.
AstraZeneca, the company Yaranov represents, has published its own research arguing that elevated aldosterone plays an outsized role in uncontrolled hypertension cases that do not respond to standard multi-drug regimens. This commercial interest does not undercut the underlying science, but readers should know a drug company helped shape the message reaching their television screens.
What This Means For Anyone Still Fighting High Numbers
For the millions of Americans managing high blood pressure, this story carries a practical takeaway worth discussing with a doctor. If medication has not worked despite genuine effort and compliance, a hormone test for aldosterone levels might uncover a fixable root cause rather than a lifelong mystery. That is useful, actionable information, not hype.
Patients who value personal responsibility and efficient healthcare should welcome this kind of plain-spoken medical reporting. It gives people a concrete question to bring to their next appointment instead of accepting vague frustration over numbers that will not move. Knowing the right question to ask is half the battle in managing any chronic condition.
World Heart Day segments come and go every year, but this one offered something rarer: a specific, testable, science-backed explanation for a problem that frustrates tens of millions of households. That alone makes it worth a second look, and a conversation with your own physician.
Sources:
youtube.com, cbsnews.com, healthline.com, astrazeneca.com
